Orchid Pharma Share Price

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma share priceon NSE and BSE is a reflection of how marketparticipants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the marketevaluates the company’s current position and its future prospects, making ͏it a key indicator of marketperception across various industries.

Orchid Pharma stock price is influenced by various factors such as earnings, product approvals, regulatory clearances, and API pricing trends. In the longer run, strategies like capacity utilization, R&D investments, and expansion into new therapeutic areas affect stock marketsentiments. All these factors must be closely monitored to have an idea about the Orchid Pharmastock price movements.

Orchid Pharmalive share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of Orchid Pharmalive price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Orchid Pharmashare͏ price today helps investors understand real-time marketsentiment, price volatility, and trading behaviour. It allows marketparticipants to evaluate short-term performance, identifypossible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Orchid Pharma Limited Company Fundamentals

a. Company Background

Orchid Pharma Limited, incorporated on 1 July 1992, is a publicly listed Indian pharmaceutical company headquartered in Chennai, Tamil Nadu 603110, India. Originally established as Orchid Chemicals & Pharmaceuticals, the company was founded to manufacture and export pharmaceutical products, particularly active pharmaceutical ingredients (APIs). It transitioned from an export‑oriented unit to a vertically integrated pharmaceutical organisation with research, manufacturing, and marketing capabilities across multiple therapeutic domains. Orchid operates in both domestic and international markets, producing APIs, finished dosage forms, and nutraceuticals, and engages in drug discovery and development. Its portfolio spans antibiotics such as cephalosporins, as well as products for central nervous system (CNS), cardiovascular, anti-infective, and anti-inflammatory segments. The company has faced industry challenges, including insolvency proceedings in 2017, culminating in a resolution plan by Dhanuka Laboratories Ltd in 2020, marking a new phase in its operational and financial strategy.

 b. Company Products

• Active Pharmaceutical Ingredients (APIs) including oral and injectable cephalosporins and other antibiotic bulk actives.

• Oral antibiotic products.

• Non-antibiotic APIs such as Phenytoin Sodium, Paroxetine HCl, Pramipexole Dihydrochloride, Quetiapine Fumarate, and related compounds.

• Finished dosage formulations including tablets, capsules, injectables, syrups, and other oral or sterile medications.

• Nutraceutical products and multi-therapeutic formulations in CNS, cardiovascular, and anti-inflammatory segments.

• Veterinary pharmaceutical products.

• Specialized formulations approved by global regulators (e.g., DCGI approvals for injectables like Cefepime and Enmetazobactam).

c. Company Revenue Model

• Revenue from manufacturing and sale of APIs to domestic and international pharmaceutical companies.

• Revenue from finished dosage forms including tablets, capsules, and injectable products.

• Export sales through global partnerships and licensing agreements in 40–60 countries.

• Income from research and development collaborations and licensing of novel compounds.

• Contract Manufacturing and Custom Research (CRAMS) services for other pharma companies.

• Revenue from strategic alliances with global pharma players supporting API supply and co-development programs.

• Domestic sales to Indian healthcare providers and institutional buyers.

d. Geographic Presence

• India: Manufacturing and R&D facilities in Tamil Nadu, including API and formulation plants.

• North America & Europe: Exports to the United States and European Union, complying with USFDA and MHRA standards.

• Asia & Middle East: Sales and distribution networks in multiple Asian countries and the Middle East through exports and partnerships.

• Global Market Reach: Partnerships and licensing arrangements span 40+ countries, providing APIs and finished products internationally.

• Alliances with multinational pharmaceutical firms to enhance market access in regulated and emerging regions.

e. Leadership

Some of the key leaders of Orchid Pharma Ltd as of February 2026 are:

• Manish Dhanuka — Executive Director & Managing Director

• Mridul Dhanuka — Executive Director & Whole-time Director

• R G Agarwal — Chairman (Non-Executive & Non-Independent Director)

• Mr. Sunil Kumar Gupta — Chief Financial Officer

• Kapil Dayya — Company Secretary & Compliance Officer

• Dr. A Chandrasekar — Vice President (Operations)

• Manoj Goyal — Independent Non-Executive Director

• Tanu Singla — Independent Non-Executive Director

• Dharam Vir — Independent Non-Executive Director

• Arjun Dhanuka — Non-Executive & Non-Independent Director

• Shubha Singh — Independent Non-Executive Director

f. Key Milestones

• 1992: Orchid Pharma Limited incorporated on 1 July 1992.

• Early 1990s: Started as an Export Oriented Unit focusing on cephalosporin antibiotics and APIs.

• 2000s: Expanded into oral and sterile products and entered global markets with USFDA and MHRA certifications.

• 2010: Sold generic injectables business (strategic divestment).

• 2017: Entered Corporate Insolvency Resolution Process (CIRP).

• 2020: Resolution plan implemented under Dhanuka Laboratories Ltd.

• 2024: Continued global product approvals and export reach, including globally approved NCE (Enmetazobactam).

g. Industry Perspective

The pharmaceutical industry is a cornerstone of global healthcare, with the global market valued at an estimated USD 1,737.97 billion in 2025 and projected to expand to about USD 2,776.74 billion by 2033, growing at a compound annual growth rate (CAGR) of approximately 6.08 % from 2026–2033 driven by chronic disease prevalence, aging populations, biologics advancements, and rising healthcare expenditure worldwide.

In India, the pharmaceutical sector is a major economic and strategic contributor, supplying nearly 20 % of the world’s generic drugs by volume and over 60 % of global vaccine demand. The domestic market was estimated at USD 66.66 billion in 2025 and is forecast to reach about USD 88.86 billion by 2030 at a CAGR of approximately 5.9 %. Other estimates suggest the Indian pharma sector will achieve a ~9.6 % CAGR, reaching ~USD 55 billion by 2030. India’s pharmaceutical exports stood at roughly USD 27.8 billion in FY 2023‑24 and aim for double‑digit growth by 2026‑27, reflecting strong global demand.

These trends indicate robust and sustained expansion in both global and Indian markets, underpinned by generics, biosimilars, APIs, vaccines, and R&D investments — positioning the industry for continued CAGR‑driven growth into the next decade.

Orchid Pharma Stock Market Presence: Listings & Index Representation

Orchid Pharma Limited got listed on the BSE (Bombay Stock Exchange) and on the NSE (National Stock Exchange). Orchid Pharma is a well-established entity in the Indian stock market, listed on major exchanges such as NSE (ORCHPHARMA) and BSE (524372). Its inclusion in prominent indices like S&P BSE Healthcare, BSE 1000, BSE Next 250 Microcap, Nifty Microcap 250 Index, Nifty Total Market, S&P BSE MidSmallCap, S&P BSE SmallCap, and S&P BSE AllCap underscores the company’s significance in India’s pharmaceutical sector.

Orchid Pharma stock price is closely tracked by retail and institutional investors. Its inclusion in major indices reflects its presence in the API and formulations business. Listing on NSE and BSE ensures liquidity, while index presence drives institutional holdings and benchmark tracking in the healthcare sector.

Orchid Pharma Stock Performance and Orchid Pharma Share Price History

Orchid Pharma share price on NSE and BSE reflects its position in the pharmaceutical sector. Performance is driven by API exports, formulation sales, R&D outcomes, and regulatory compliance. Investors compare Orchid Pharma share price today with sectoral indices and pharmaceutical peers to gauge relative performance. These underlying factors are often visible through real market movements across different periods.

Orchid Pharma share price has experienced significant fluctuations over time. The company’s stock has shown periods of sharp gains and phases of consolidation. The early 2000s witnessed growth, driven by expansion in the API business. During the 2008 financial crisis, Orchid Pharma stock price experienced volatility. Between 2012 and 2017, the stock delivered varied returns. From 2018 onwards, Orchid Pharma share price became volatile, while recent movements reflect sector trends.

Orchid Pharma share price reached a 52-week high of ₹899.00 and a 52-week low of ₹489.00. These levels capture impacts of regulatory changes, growth expectations, and earnings visibility, providing context for the stock’s historical performance. Orchid Pharma share price has shown long-term wealth creation over a 10-year horizon, with returns of 1,268.47%.

Orchid Pharma share price history shows a 1-day return of 3.95%, while 1-week returns stood at -1.25%. The 1-month return was -15.69%, and 3-month returns were -31.17%. Over a 6-month period, Orchid Pharma share price declined by -27.92%, and 1-year returns were -32.65%. However, over 3 years, Orchid Pharma share price gained 37.55%. The 5-year return was -74.44%, while the 10-year return stood at 1,268.47%.

When compared to benchmarks, Orchid Pharma share price underperformed in the 1-year period, with the stock returning -32.65% against Nifty50’s -1.53% and Sensex’s -3.52%. The industry returned 6.33% and the sector returned 6.16% during the same period. Over 3 years, Orchid Pharma share price delivered 37.55%, closely matching Nifty50’s 37.54% and outperforming Sensex’s 30.85%. Over 10 years, Orchid Pharma share price delivered exceptional returns of 1,268.47%, significantly outperforming Nifty50’s 202.03%, Sensex’s 197.08%, and the sector’s 282.70%.

Orchid Pharma stock price seasonality data shows quarterly return patterns. The 5-year average returns show Q1 at -12.33%, Q2 at -6.40%, Q3 at -2.87%, and Q4 at 15.88%. In 2026, Orchid Pharma stock price declined -30.09% in Q1. In 2025, returns were -57.28% in Q1, -7.62% in Q2, -2.00% in Q3, and 8.64% in Q4. The year 2024 saw strong positive returns of 47.96% in Q1, 9.06% in Q2, 19.30% in Q3, and 32.50% in Q4. In 2023, returns stood at 5.25% in Q1, 30.79% in Q2, 6.65% in Q3, and 33.87% in Q4.

Orchid Pharma stock price deep dive data shows the stock opened at ₹511.45 with a day high of ₹550.95 and low of ₹512.50, closing at ₹531.65. The distance from the high stood at 3.50% and from the low at 3.74%. Over the week, the stock ranged between ₹550.95 and ₹502.95. Monthly highs and lows were ₹642 and ₹489, with a distance of 17.19% from the high and 8.72% from the low. Quarterly ranges touched ₹805 high and ₹489 low, with the stock trading 33.96% below the high. The half-year and one-year highs reached ₹899, with the stock trading 40.86% below the peak.

Orchid Pharma Investor Relevance and Role in Portfolio

Orchid Pharma is a holding in pharmaceutical-sector and small-cap portfolios, offering exposure to API manufacturing and finished dosage formulations. Inclusion in indices like S&P BSE Healthcare and Nifty Smallcap 250 underscores its relevance in the pharma ecosystem. The company’s focus on anti-infectives and regulatory compliance makes it a consideration for sector-specific allocations.

Orchid Pharma equity is held by a mix of domestic and international institutional investors. Top institutional stakeholders include Quant Mutual Fund, Kotak Mahindra Trustee Company, Invesco India, and UTI Small Cap Fund. Mutual funds hold 18.01% of the company. Quant Mutual Fund holds 6.83%, Kotak Mahindra holds 3.51%, Invesco holds 3.20%, and UTI holds 2.29%. Foreign Portfolio Investors Category I hold 1.12% and Category II hold 0.05%.

Orchid Pharma stock is monitored in derivatives markets, where open interest patterns reflect expectations on API pricing, regulatory approvals, and sector trends. Technical indicators such as RSI, MACD, and MFI provide additional insight into short-term momentum shifts in Orchid Pharma stock price.

Orchid Pharma’s beta has varied across different periods, reflecting the stock’s volatility characteristics. The long-term beta stands at 2.06. Daily beta over a one-month range is 1.29, while over a three-month range it is 1.26. Weekly beta over a one-year range is 1.08, and over a two-year range it is 0.880. The 2-week beta over a two-year range is 1.30, while the monthly beta over a two-year range is 0.878. These figures indicate that Orchid Pharma share price has shown higher volatility compared to the broader market over certain periods. The standard deviation values across these periods range from 2.45 to 16.74, reflecting varying levels of price fluctuation.

Orchid Pharma Sectoral Relevance and Peer Positioning

Orchid Pharma sector relevance stems from its expertise in antibiotic API manufacturing, particularly cephalosporins, and its presence in regulated markets, establishing it as a key player in India’s pharmaceutical sector. Peer comparisons with companies like Aurobindo Pharma, Cipla, Sun Pharma, Lupin, and Alkem Laboratories focus on API capacity, formulation portfolio, regulatory approvals, and R&D pipeline rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence.

Orchid Pharma’s sectoral importance is reflected in financial and market metrics that demonstrate its scale and stability.

Orchid Pharma market cap stands at ₹26.96 billion as of March 2026. The market cap decreased by -29.95% from the previous period. In December 2025, the market cap stood at ₹38.49 billion, reflecting a -58.00% change. December 2024 recorded ₹91.65 billion with a growth of 153.62%. December 2023 saw ₹36.14 billion, up 143.20%. In December 2022, the market cap was ₹14.86 billion, down -7.81%. December 2021 recorded ₹16.12 billion, a 223.64% increase. The overall growth from November 2020 to March 2026 represents a 3,607.28% increase.

Orchid Pharma’s earnings has fluctuated significantly over the past decade. Between FY15 and FY17, the company faced substantial losses of -₹196.7 crore, -₹279.1 crore, and -₹352.8 crore due to high operating expenses and operational challenges. FY18 marked a recovery with a net profit of ₹69.4 crore. FY19 and FY20 reported losses of -₹131.1 crore and -₹116.5 crore. From FY21 onwards, profitability improved steadily. FY22 reported ₹46.3 crore, FY23 recorded ₹92.2 crore, and FY24 showed ₹99.7 crore. The 1-year growth in FY24 stood at 8.1%, while the 3-year CAGR was approximately 18.6%.

Orchid Pharma EPS have shown a strong recovery trajectory. In Mar 2021, EPS stood at -₹28.55. Mar 2022 improved to -₹0.48. Mar 2023 turned positive at ₹11.35. Mar2024 increased to ₹18.17, representing a growth of 60.09%. Mar 2025 further improved to ₹19.65, showing an 8.15% increase. This consistent upward trend from negative to positive EPS reflects improving operational efficiency and profitability. The EPS growth from Mar 2021 to Mar 2025 represents a significant turnaround for the company.

Orchid Pharma’s P/E ratio has varied significantly across financial years. At the end of FY2025, the P/E ratio stood at 39.54. In FY2024, the ratio was 57.52. FY2023 recorded 33.87. FY2022 showed 0.00 due to negative earnings. FY2021 also showed 0.00. The current P/E ratio as of March 2026 stands at 141.02, reflecting market expectations around the company’s earnings recovery and growth prospects. The ratio has shown significant variation based on the company’s profitability trajectory and market sentiment toward the pharmaceutical sector.

SUMMARY

Orchid Pharma Limited is a pharmaceutical company with operations in API and formulations manufacturing. The company has demonstrated a strong recovery in earnings over recent years, with consistent improvements in net profit and EPS. Orchid Pharma share price has shown significant long-term returns of 1,268.47% over 10 years, though it has experienced volatility in shorter timeframes. The stock maintains presence across multiple indices and holds interest from institutional investors.